Publicação
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds
| dc.contributor.author | Moranguinho, Inês | |
| dc.contributor.author | Taveira, Nuno | |
| dc.contributor.author | Bártolo, Inês | |
| dc.date.accessioned | 2024-01-18T18:41:03Z | |
| dc.date.available | 2024-01-18T18:41:03Z | |
| dc.date.issued | 2023-03-21 | |
| dc.date.updated | 2023-10-25T13:04:56Z | |
| dc.description | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | pt_PT |
| dc.description.abstract | Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, some do not work as well, or do not work at all, for HIV-2. This is the case for non-nucleoside reverse transcriptase inhibitors (NNRTIs), the fusion inhibitor enfuvirtide (T-20), most protease inhibitors (PIs), the attachment inhibitor fostemsavir and most broadly neutralizing antibodies. Integrase inhibitors work well against HIV-2 and are included in first-line therapeutic regimens for HIV-2-infected patients. However, rapid emergence of drug resistance and cross-resistance within each drug class dramatically reduces second-line treatment options. New drugs are needed to treat infection with drug-resistant isolates. Here, we review the therapeutic armamentarium available to treat HIV-2-infected patients, as well as promising drugs in development. We also review HIV-2 drug resistance mutations and resistance pathways that develop in HIV-2-infected patients under treatment. | pt_PT |
| dc.description.sponsorship | This work was supported by Fundação para a Ciência e Tecnologia (FCT), Portugal, Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in Portuguese speaking countries in Africa (project 332821690). Inês Moranguinho was supported by PhD fellowship from Fundação para a Ciência e Tecnologia (FCT), Portugal (reference SFRH/BD/131062/2017) Inês Bártolo is supported by FCT through Norma Transitória—DL57/2016/CP1376/CT0012. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Moranguinho I, Taveira N, Bártolo I. Antiretroviral treatment of hiv-2 infection: available drugs, resistance pathways, and promising new compounds. IJMS [Internet]. 21 de março de 2023;24(6):5905. Disponível em: https://www.mdpi.com/1422-0067/24/6/5905 | pt_PT |
| dc.identifier.doi | 10.3390/ijms24065905 | pt_PT |
| dc.identifier.slug | cv-prod-3359445 | |
| dc.identifier.uri | http://hdl.handle.net/10451/61922 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.relation | Gene therapy for HIV cure using RNA replicons. | |
| dc.relation.publisherversion | https://www.mdpi.com/1422-0067/24/6/5905 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | HIV-2 | pt_PT |
| dc.subject | HIV-2 treatment | pt_PT |
| dc.subject | antiretroviral drugs | pt_PT |
| dc.subject | resistance mutations | pt_PT |
| dc.subject | resistance pathways | pt_PT |
| dc.title | Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Gene therapy for HIV cure using RNA replicons. | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F131062%2F2017/PT | |
| oaire.citation.issue | 6 | pt_PT |
| oaire.citation.startPage | 5905 | pt_PT |
| oaire.citation.title | International Journal of Molecular Sciences | pt_PT |
| oaire.citation.volume | 24 | pt_PT |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.cv.cienciaid | 661E-F5CB-F85A | Inês Bártolo | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isProjectOfPublication | 250af1fe-5815-4cce-8995-b19152bab737 | |
| relation.isProjectOfPublication.latestForDiscovery | 250af1fe-5815-4cce-8995-b19152bab737 |